That's a completely different project, actually. We can look at how pricing is done in different jurisdictions and see whether it's cheaper or not cheaper, but why that is the case is extremely difficult to ascertain, because there are many different factors with regard to how different governments negotiate with pharmaceutical companies and how pharmaceutical companies behave. That's a completely different issue.
